CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its New Drug Submission (NDS) for BRUKINSA® (zanubrutinib) for the treatment of patients with Waldenström’s… Continue reading →
Waldenström Macroglobulinemia (WM) is a low-grade B-cell lymphoproliferative disorder characterized by bone marrow infiltration with lymphoplasmacytic cells, together with an immunoglobulin M (IgM) monoclonal gammopathy. An estimated 1000–1500 new cases of WM are diagnosed in… Continue reading →
The International Waldenstrom’s Macroglobulinemia Foundation invites you to join us for the second installment in our 2020 IWMF Global Educational Webinar series. Through this free interactive webinar series, you will learn from the best and brightest minds in WM research,… Continue reading →
Over the last 20 years the WMFC members have generously supported a tremendous amount of research. Some of it has been groundbreaking, helping change the lives of Canadian WMers for the better. As an organization, the WMFC is now focusing… Continue reading →
Dr. Zachary Hunter recently spoke at an Atlantic Support Group Zoom Meeting. Click on the link below to view his presentation entitled “What is New in Waldenstrom’s Macroglobulinemia Research?” His talk is followed by a question and answer session.
-On Friday 19 June- over 260 people joined our webinar, in partnership with Lymphoma Action, to hear our panel of UK experts answer some of the most commonly asked questions around COVID-19 and Waldenstrom’s macroglobulinaemia (WM).… Continue reading →